Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Jun 26, 2024

BUY
$210.76 - $249.51 $210 - $249
1 New
1 $290,000
Q1 2024

May 13, 2024

BUY
$210.76 - $249.51 $2,950 - $3,493
14 New
14 $3.42 Million
Q4 2023

Jun 26, 2024

SELL
$214.88 - $256.94 $3,008 - $3,597
-14 Closed
0 $277,000
Q4 2023

Feb 15, 2024

BUY
$214.88 - $256.94 $0 - $0
0 New
0 $0
Q3 2023

Nov 15, 2023

SELL
$211.82 - $248.24 $46,812 - $54,861
-221 Closed
0 $0
Q2 2023

Aug 08, 2023

SELL
$205.19 - $232.99 $615 - $698
-3 Reduced 1.34%
221 $8.66 Million
Q1 2023

May 12, 2023

SELL
$212.99 - $276.17 $11,501 - $14,913
-54 Reduced 19.42%
224 $2.21 Million
Q4 2022

Feb 15, 2023

SELL
$205.95 - $280.43 $1.02 Million - $1.39 Million
-4,947 Reduced 94.68%
278 $12.3 Million
Q3 2022

Nov 03, 2022

BUY
$203.3 - $244.17 $630,433 - $757,171
3,101 Added 146.0%
5,225 $2.34 Million
Q2 2022

Aug 05, 2022

SELL
$174.81 - $241.14 $442,269 - $610,084
-2,530 Reduced 54.36%
2,124 $351,000
Q1 2022

May 13, 2022

BUY
$166.16 - $213.96 $450,293 - $579,831
2,710 Added 139.4%
4,654 $3.01 Million
Q4 2021

Feb 11, 2022

BUY
$184.32 - $216.08 $357,949 - $419,627
1,942 Added 97100.0%
1,944 $360,000
Q3 2021

Nov 12, 2021

SELL
$179.86 - $214.88 $2,877 - $3,438
-16 Reduced 88.89%
2 $185,000
Q2 2021

Aug 11, 2021

SELL
$170.47 - $211.93 $852 - $1,059
-5 Reduced 21.74%
18 $179,000
Q1 2021

May 17, 2021

BUY
$153.94 - $174.85 $461 - $524
3 Added 15.0%
23 $3.92 Million
Q4 2020

Feb 16, 2021

BUY
$101.87 - $151.79 $2,037 - $3,035
20 New
20 $3,000
Q2 2019

Jul 26, 2019

SELL
$76.06 - $120.81 $29,663 - $47,115
-390 Closed
0 $0
Q1 2019

Apr 19, 2019

BUY
$107.15 - $126.84 $41,788 - $49,467
390 New
390 $46,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.5B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Financial Gravity Asset Management, Inc. Portfolio

Follow Financial Gravity Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.